95 related articles for article (PubMed ID: 14747050)
1. A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer.
Lin J; Zahurak M; Beer TM; Ryan CJ; Wilding G; Mathew P; Morris M; Callahan JA; Gordon G; Reich SD; Carducci MA; Antonarakis ES
Urol Oncol; 2013 Jul; 31(5):581-8. PubMed ID: 21816640
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen half-life: a new predictor of progression-free survival and overall survival in Chinese prostate cancer patients.
Lin GW; Yao XD; Zhang SL; Dai B; Ma CG; Zhang HL; Shen YJ; Zhu Y; Zhu YP; Shi GH; Qin XJ; Ye DW
Asian J Androl; 2009 Jul; 11(4):443-50. PubMed ID: 19182820
[TBL] [Abstract][Full Text] [Related]
3. Updates on Management of Biochemical Recurrent Prostate Cancer.
Cooley LF; Srivastava A; Shore ND
Curr Treat Options Oncol; 2024 Mar; 25(3):284-292. PubMed ID: 38286895
[TBL] [Abstract][Full Text] [Related]
4. Novel metastatic burden-stratified risk model in de novo metastatic hormone-sensitive prostate cancer.
Shiota M; Terada N; Kitamura H; Kojima T; Saito T; Yokomizo A; Kohei N; Goto T; Kawamura S; Hashimoto Y; Takahashi A; Kimura T; Tabata KI; Tomida R; Hashimoto K; Sakurai T; Shimazui T; Sakamoto S; Kamiyama M; Tanaka N; Mitsuzuka K; Kato T; Narita S; Yasumoto H; Teraoka S; Kato M; Osawa T; Nagumo Y; Matsumoto H; Enokida H; Sugiyama T; Kuroiwa K; Inoue T; Sugimoto M; Mizowaki T; Kamoto T; Nishiyama H; Eto M;
Cancer Sci; 2021 Sep; 112(9):3616-3626. PubMed ID: 34145921
[TBL] [Abstract][Full Text] [Related]
5. Prolonged remission of fulminant castrate-resistant prostate cancer: a case report.
Bilen MA; General R; Tu SM
Clin Genitourin Cancer; 2011 Dec; 9(2):133-6. PubMed ID: 21729684
[TBL] [Abstract][Full Text] [Related]
6. Antibody responses to galectin-8, TARP and TRAP1 in prostate cancer patients treated with a GM-CSF-secreting cellular immunotherapy.
Nguyen MC; Tu GH; Koprivnikar KE; Gonzalez-Edick M; Jooss KU; Harding TC
Cancer Immunol Immunother; 2010 Sep; 59(9):1313-23. PubMed ID: 20499060
[TBL] [Abstract][Full Text] [Related]
7. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.
Scher HI; Halabi S; Tannock I; Morris M; Sternberg CN; Carducci MA; Eisenberger MA; Higano C; Bubley GJ; Dreicer R; Petrylak D; Kantoff P; Basch E; Kelly WK; Figg WD; Small EJ; Beer TM; Wilding G; Martin A; Hussain M;
J Clin Oncol; 2008 Mar; 26(7):1148-59. PubMed ID: 18309951
[TBL] [Abstract][Full Text] [Related]
8. Minimal residual disease in prostate cancer patients after primary treatment: theoretical considerations, evidence and possible use in clinical management.
Murray NP
Biol Res; 2018 Sep; 51(1):32. PubMed ID: 30180883
[TBL] [Abstract][Full Text] [Related]
9. PSA Doubling Time and Absolute PSA Predict Metastasis-free Survival in Men With Biochemically Recurrent Prostate Cancer After Radical Prostatectomy.
Markowski MC; Chen Y; Feng Z; Cullen J; Trock BJ; Suzman D; Antonarakis ES; Paller CJ; Rosner I; Han M; Walsh PC; Partin AW; Eisenberger M
Clin Genitourin Cancer; 2019 Dec; 17(6):470-475.e1. PubMed ID: 31530439
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer trajectory-map: clinical decision support system for prognosis management of radical prostatectomy.
Park J; Rho MJ; Moon HW; Park YH; Kim CS; Jeon SS; Kang M; Lee JY
Prostate Int; 2021 Mar; 9(1):25-30. PubMed ID: 33912511
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of the prostate-specific antigen doubling time prior to and following radical prostatectomy to predict the outcome of prostate cancer.
Takeuchi H; Ohori M; Tachibana M
Mol Clin Oncol; 2017 Feb; 6(2):249-254. PubMed ID: 28357104
[TBL] [Abstract][Full Text] [Related]
12. Relationships between times to testosterone and prostate-specific antigen rises during the first off-treatment interval of intermittent androgen deprivation are prognostic for castration resistance in men with nonmetastatic prostate cancer.
Kuo KF; Hunter-Merrill R; Gulati R; Hall SP; Gambol TE; Higano CS; Yu EY
Clin Genitourin Cancer; 2015 Feb; 13(1):10-6. PubMed ID: 25242417
[TBL] [Abstract][Full Text] [Related]
13. PSA Decrease with Fulvestrant Acetate in a Hormone-Resistant Metastatic Prostate Cancer Patient: A Case Report.
Gasent Blesa JM; Alberola Candel V
Case Rep Oncol; 2009 Apr; 2(1):72-76. PubMed ID: 20740149
[TBL] [Abstract][Full Text] [Related]
14. Challenges in clinical prostate cancer: role of imaging.
Kelloff GJ; Choyke P; Coffey DS;
AJR Am J Roentgenol; 2009 Jun; 192(6):1455-70. PubMed ID: 19457806
[TBL] [Abstract][Full Text] [Related]
15. Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time.
Arlen PM; Bianco F; Dahut WL; D'Amico A; Figg WD; Freedland SJ; Gulley JL; Kantoff PW; Kattan MW; Lee A; Regan MM; Sartor O;
J Urol; 2008 Jun; 179(6):2181-5; discussion 2185-6. PubMed ID: 18423743
[TBL] [Abstract][Full Text] [Related]
16. Down regulation of PSA by C/EBPalpha is associated with loss of AR expression and inhibition of PSA promoter activity in the LNCaP cell line.
Yin H; Radomska HS; Tenen DG; Glass J
BMC Cancer; 2006 Jun; 6():158. PubMed ID: 16774685
[TBL] [Abstract][Full Text] [Related]
17. ICI 182,780-regulated gene expression in DU145 prostate cancer cells is mediated by estrogen receptor-beta/NFkappaB crosstalk.
Leung YK; Gao Y; Lau KM; Zhang X; Ho SM
Neoplasia; 2006 Apr; 8(4):242-9. PubMed ID: 16756716
[TBL] [Abstract][Full Text] [Related]
18. Prostate-specific antigen doubling time and survival in patients with advanced metastatic prostate cancer.
Loberg RD; Fielhauer JR; Pienta BA; Dresden S; Christmas P; Kalikin LM; Olson KB; Pienta KJ
Urology; 2003 Dec; 62 Suppl 1():128-33. PubMed ID: 14747050
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific antigen doubling time in the identification of patients at risk for progression after treatment and biochemical recurrence for prostate cancer.
Cannon GM; Walsh PC; Partin AW; Pound CR
Urology; 2003 Dec; 62 Suppl 1():2-8. PubMed ID: 14747037
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
